Bispecific Conjugate Compounds for Alpha-Synuclein Aggregate Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of therapeutics that effectively target α-synuclein aggregation in neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, which are characterized by the abnormal accumulation of α-synuclein aggregates in neurons and glial cells.
Innovation Solution
Development of bispecific conjugate compounds that include an E3 ubiquitin ligase binding moiety and an α-synuclein protein binding moiety, which facilitate the degradation of α-synuclein aggregates through proteasome-mediated degradation by binding to and ubiquitinating α-synuclein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics are used, then general symptom management is achieved, but α-synuclein aggregation is not effectively targeted
Solution Approach 1:
The therapeutic compound is segmented into two distinct functional moieties: an E3 ligase binding domain and an α-synuclein binding domain. This segmentation allows each domain to independently perform its specific function - recruiting the E3 ligase and recognizing the target protein respectively - thereby achieving reliable and specific targeting of α-synuclein aggregates that conventional single-function therapeutics cannot accomplish
Solution Approach 2:
The invention creates a composite therapeutic molecule by covalently linking two different functional domains (E3 ligase binder and α-synuclein binder) into a single conjugate compound. This composite structure integrates the capabilities of two separate therapeutic agents, enabling simultaneous recruitment of the degradation machinery and specific binding to the target aggregate, thus resolving the contradiction between reliability and adaptability
2Object-generated harmful factors
If α-synuclein aggregates accumulate, then neurodegenerative disease pathology progresses, but effective therapeutic intervention is lacking
Solution Approach 1:
The invention converts the harmful α-synuclein aggregates into a therapeutic target by designing a compound that specifically binds to these aggregates and recruits the cell's own ubiquitin-proteasome system to degrade them. The harmful aggregates become the very target that enables the therapeutic mechanism, transforming the pathological feature into a benefit for treatment
Solution Approach 2:
The bispecific conjugate acts as an intermediary molecule that bridges the E3 ubiquitin ligase and the α-synuclein aggregates. It facilitates the interaction between the degradation machinery and the target protein by simultaneously binding both, enabling the proteasome to recognize and degrade the aggregates that would otherwise be invisible to the cellular degradation system
3Productivity
If proteasome-mediated degradation is induced, then α-synuclein aggregates are reduced, but complex compound design is required
Solution Approach 1:
The invention merges two previously separate therapeutic functions into a single conjugate compound: the ability to bind E3 ligase and the ability to bind α-synuclein. This merging eliminates the need for complex combination therapies or multi-step delivery systems, achieving high productivity in aggregate degradation through a streamlined single-molecule approach despite the increased molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce α-synuclein aggregates, potentially treating or preventing neurodegenerative diseases by decreasing the levels of Lewy bodies and reducing the severity or progression of synucleinopathies.
Implementation Method 1
facilitate the degradation of α-synuclein aggregates through proteasome-mediated degradation by binding to and ubiquitinating α-synuclein aggregates
Implementation Method 2
facilitate the degradation of α-synuclein aggregates through proteasome-mediated degradation
Data Source
AI summary
The present disclosure provides compounds, compositions and methods useful for the treatment of neurodegenerative diseases, in particular synucleinopathies.